StreetInsider.com News Articles

Form 4 PDS Biotechnology Corp For: Oct 18 Filed by: Ramsdell Deborah

Tue, 20 Oct 2026 20:21:00 -0400

si-local-file:///var/storage/secattach/20261020/27211598.html

Form 4 PDS Biotechnology Corp For: Oct 18 Filed by: Wendel Bruce

Tue, 20 Oct 2026 20:20:00 -0400

si-local-file:///var/storage/secattach/20261020/27211597.html

Form 3 PDS Biotechnology Corp For: Oct 18 Filed by: Wendel Bruce

Tue, 20 Oct 2026 20:16:00 -0400

si-local-file:///var/storage/secattach/20261020/27211592.html

Form 3 PDS Biotechnology Corp For: Oct 18 Filed by: Ramsdell Deborah

Tue, 20 Oct 2026 20:16:00 -0400

si-local-file:///var/storage/secattach/20261020/27211591.html

Form 8-K PDS Biotechnology Corp For: Oct 18

Tue, 20 Oct 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20261020/27206944.html

PDS Biotech adds three directors amid four board resignations

Tue, 20 Oct 2026 08:00:37 -0400

PDS Biotechnology Corporation (Nasdaq: PDSB) announced the appointment of John Dawson CBE, Deborah Ramsdell, and Bruce Wendel to its board of directors, effective October 18, 2026. The appointments coincide with the resignations of four existing board members: Stephen Glover, Kamil Ali-Jackson, Gregory Freitag, and Otis Brawley, also effective October 18, 2026.

The Princeton, N.J.-based company said the three incoming directors bring experience in corporate development, commercialization, and regulatory affairs. The board changes come as PDS Biotech advances its cancer immunotherapy candidate PDS0301 toward a Phase 3 trial in metastatic colorectal cancer and pursues partnership opportunities for PDS0101.

Dawson has served as executive

PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors

Tue, 20 Oct 2026 08:00:00 -0400

John Dawson CBE, Deborah Ramsdell and Bruce Wendel bring corporate development, commercialization, and regulatory experience to the Company as it advances PDS0301 toward Phase 3 trial in Metastatic Colorectal Cancer (mCRC) and PDS0101 toward potential partnerships

PRINCETON, N.J., Oct. 20, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the appointments of John Dawson CBE, Deborah Ramsdell, and Bruce Wendel to the Company’s Board of Directors (the “Board”), effective as of October 18, 2026. The appointments

PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors

Tue, 20 Oct 2026 08:00:00 -0400

Form S-3 PDS Biotechnology Corp

Wed, 14 Oct 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20261014/27187345.html

Form 8-K PDS Biotechnology Corp For: Oct 06

Tue, 06 Oct 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20261006/27152293.html

PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases

Tue, 06 Oct 2026 08:00:00 -0400

Virtual Event Featuring Jonathan M. Hernandez, M.D, Investigator, Surgical Oncology Program, NCI/CCR, to Be Held October 15, 2026, at 8am ET

PRINCETON, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a virtual key opinion leader (KOL) event featuring Jonathan M. Hernandez, M.D, an Investigator with Surgical Oncology Program at the National Cancer Institute’s Center for Cancer Research. Dr. Hernandez will join company management to discuss clinical outcomes

PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases

Tue, 06 Oct 2026 08:00:00 -0400

Virtual Event Featuring Jonathan M. Hernandez, M.D, Investigator, Surgical Oncology Program, NCI/CCR, to Be Held October 15, 2026, at 8am ET

Form 8-K PDS Biotechnology Corp For: Sep 12

Tue, 22 Sep 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260922/27091853.html

Form 8-K PDS Biotechnology Corp For: Sep 22

Tue, 22 Sep 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260922/27088004.html

PDS Biotech publishes phase 2 head and neck cancer trial results

Tue, 22 Sep 2026 08:00:39 -0400

PDS Biotechnology Corporation (Nasdaq: PDSB) announced the publication of results from its VERSATILE-002 phase 2 clinical trial in the September 17, 2026, issue of JAMA Oncology, evaluating PDS0101 combined with pembrolizumab in patients with HPV16-positive recurrent and/or metastatic head and neck squamous cell carcinoma.

The trial enrolled 88 patients across 26 oncology centers in the U.S., U.K., and Ireland. Among the 53 immune checkpoint inhibitor (ICI)-naïve patients with PD-L1 CPS ≥1, the median overall survival (mOS) was 39.3 months. The company noted that the published result for standard-of-care pembrolizumab or pembrolizumab plus chemotherapy is 17.9 months, though no head-to-head trials were

PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncolog

Tue, 22 Sep 2026 08:00:00 -0400

39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor naïve patients

Company continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC) while pursuing partnership strategy for PDS0101

PRINCETON, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the publication of results from a Phase 2 trial evaluating PDS0101, its HPV16-targeted immunotherapy, in combination with pembrolizumab in the September 17, 2026, issue of JAMA

PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncolog

Tue, 22 Sep 2026 08:00:00 -0400

39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor naïve patients

Company continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC) while pursuing partnership strategy for PDS0101

PRINCETON, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the publication of results from a Phase 2 trial evaluating PDS0101, its HPV16-targeted immunotherapy, in combination with pembrolizumab in the September 17, 2026, issue of JAMA

Form SCHEDULE 13D PDS Biotechnology Corp Filed by: Nant Capital, LLC

Mon, 21 Sep 2026 21:56:00 -0400
si-local-file:///var/storage/secattach/20260921/27086472.html

Form 3 PDS Biotechnology Corp For: Sep 14 Filed by: SOON-SHIONG PATRICK

Mon, 21 Sep 2026 20:40:00 -0400
si-local-file:///var/storage/secattach/20260921/27086411.html

Form 3 PDS Biotechnology Corp For: Sep 14 Filed by: Banaag Arnold James

Mon, 21 Sep 2026 20:39:00 -0400
si-local-file:///var/storage/secattach/20260921/27086410.html

Form 8-K PDS Biotechnology Corp For: Sep 21

Mon, 21 Sep 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260921/27085385.html

Form 3 PDS Biotechnology Corp For: Sep 12 Filed by: Trochimiuk Janetta

Fri, 18 Sep 2026 16:34:00 -0400
si-local-file:///var/storage/secattach/20260918/27080932.html

Form 8-K PDS Biotechnology Corp For: Sep 12

Mon, 14 Sep 2026 16:11:00 -0400
si-local-file:///var/storage/secattach/20260914/27058506.html

PDS Biotech closes $11.3M PIPE led by Nant Capital, adds Soon-Shiong

Mon, 14 Sep 2026 10:30:19 -0400

PDS Biotechnology Corporation (Nasdaq: PDSB) completed the initial closing of a private investment in public equity (PIPE) transaction, raising approximately $11.3 million in gross proceeds, with the round led by Nant Capital, LLC.

The total PIPE is structured for up to $22.3 million, with a contingent milestone closing of up to $11 million that will be triggered upon the company's submission of a Phase 3 clinical trial protocol for its drug candidate PDS0301 to the FDA. At that milestone closing, Nant Capital and AB Group Ltd. would be obligated to invest $10 million and $1 million, respectively.

At the initial closing, the

PDS Biotech closes $11.3M PIPE led by Nant Capital, adds Soon-Shiong

Mon, 14 Sep 2026 10:30:19 -0400

PDS Biotechnology Corporation (Nasdaq: PDSB) completed the initial closing of a private investment in public equity (PIPE) transaction, raising approximately $11.3 million in gross proceeds, with the round led by Nant Capital, LLC.

The total PIPE is structured for up to $22.3 million, with a contingent milestone closing of up to $11 million that will be triggered upon the company's submission of a Phase 3 clinical trial protocol for its drug candidate PDS0301 to the FDA. At that milestone closing, Nant Capital and AB Group Ltd. would be obligated to invest $10 million and $1 million, respectively.

At the initial closing, the